Skip to main content
. Author manuscript; available in PMC: 2022 Feb 1.
Published in final edited form as: Exp Hematol. 2020 Dec 2;94:20–25. doi: 10.1016/j.exphem.2020.11.008

Figure 1: Schematic summary of ossicle and bioreactor technologies.

Figure 1:

Approaches for engineering tri-dimensional hematopoietic environments. A. In vivo ossicle models. B. Ex vivo bioreactor model. ALL: acute lymphoblastic leukemia; AML: acute myeloid leukemia; APL: acute promyelocytic leukemia; BMP-2: bone morphogenetic protein; FBS: fetal bovine serum; FGF-2: fibroblast growth factor-2; FLT3-L: Fms-related tyrosine kinase 3 ligand; G-CSF: granulocyte colony stimulating factor; HSPC: hematopoietic stem and progenitor cells; hMSC: human mesenchymal stromal cells; hPTH: human parathyroid hormone; IL-3: interleukin-3; MPN: myeloproliferative neoplasm; SCF: stem cell factor; TPO: thrombopoietin.